36. Winlevi

Acne
In the long run, the company expects dermatologists will use Winlevi in combination with existing treatments to address multiple facets of acne. (Getty Images)

Active ingredient: Clascoterone cream 1%
Disease: Acne
Peak sales estimate: ~$400 million
Approved: Aug. 27
Company: Cassiopea

The scoop: Before Cassiopea’s August approval for acne med Winlevi, it had been decades since the FDA signed off on a novel treatment in the field. But like other drugmakers that have won approvals this year, Cassiopea had to adapt after the COVID-19 pandemic forced a delayed launch. Cassiopea plans to launch in March 2021 and is working to incorporate lessons from other companies that have launched new drugs amid the pandemic. In the long run, the company expects dermatologists will use Winlevi in combination with existing treatments to address multiple facets of the condition, such as clogged hair follicles and inflammation. Doctors have indicated they’re enthusiastic about the new option, CEO Diana Harbort said in an interview, and the company expects “widespread acceptance and use.” When Cassiopea launches Winlevi, the new drug will face off against branded options from Galderma, Bausch & Lomb and Menlo. – Eric Sagonowsky

36. Winlevi